Malcisbo
Malcisbo AG is a biopharmaceutical company founded in 2010 as a spin-off from ETH Zurich, specializing in glycoengineering technologies to develop novel and efficient glycoconjugate vaccines. Their mission is to reduce antibiotic treatment in farming animals to prevent antibiotic resistance, focusing on bacterial diseases affecting animal health, human food safety, and zoonotic diseases. They develop vaccines targeting pathogens such as Campylobacter and Actinobacillus pleuropneumoniae, aiming to significantly reduce the use of antibiotics in agriculture.
Industries
Nr. of Employees
small (1-50)
Malcisbo
Products
Glycoengineered live oral poultry vaccine targeting Campylobacter jejuni
A live, orally delivered glycoconjugate vaccine for broiler chickens that expresses conserved Campylobacter N-glycans on a bacterial vector to reduce intestinal Campylobacter loads and subsequent food contamination.
Polyvalent glycoengineered swine vaccine targeting Actinobacillus pleuropneumoniae (APP)
A polyvalent glycoconjugate vaccine candidate for pigs that expresses specific APP sugar moieties on a bacterial vector to provide cross-serotype protection against pleuropneumonia.
Glycoengineered live oral poultry vaccine targeting Campylobacter jejuni
A live, orally delivered glycoconjugate vaccine for broiler chickens that expresses conserved Campylobacter N-glycans on a bacterial vector to reduce intestinal Campylobacter loads and subsequent food contamination.
Polyvalent glycoengineered swine vaccine targeting Actinobacillus pleuropneumoniae (APP)
A polyvalent glycoconjugate vaccine candidate for pigs that expresses specific APP sugar moieties on a bacterial vector to provide cross-serotype protection against pleuropneumonia.
Services
Research and development of carbohydrate-based (glycoconjugate) vaccines for bacterial pathogens affecting farm animals, delivered via partnership arrangements and collaborative projects.
Research and development of carbohydrate-based (glycoconjugate) vaccines for bacterial pathogens affecting farm animals, delivered via partnership arrangements and collaborative projects.
Expertise Areas
- Glycoconjugate vaccine development
- Glycobiology and glycoengineering
- Animal vaccine development (poultry and swine)
- Preclinical in vivo challenge models
Key Technologies
- Glycoengineering
- Glycoconjugate vaccine methods
- Recombinant bacterial surface glycan expression
- Live bacterial vector vaccine platforms
News & Updates
Malcisbo was selected as an emerging company to present at the European Animal Health Investment Forum in London, February 24-26, 2020.
Malcisbo was selected as an emerging company to present at the Animal Health Investment Forum in London, February 2019.
Malcisbo received a grant from VetBioNet, a European Union Horizon 2020 project, to perform an APP challenge study at Wageningen Bioveterinary Research in Lelystad, NL.
Malcisbo was selected as an emerging company to present at the European Animal Health Investment Forum in London, February 2017.
Malcisbo participated in a CTI-funded research project on developing a vaccine against Actinobacillus pleuropneumoniae (APP).
Publication in PLOS Pathogens on parasite glycobiology.
Malcisbo was selected as an emerging company to present at the European Animal Health Investment Forum in London, February 24-26, 2020.
Malcisbo was selected as an emerging company to present at the Animal Health Investment Forum in London, February 2019.
Malcisbo received a grant from VetBioNet, a European Union Horizon 2020 project, to perform an APP challenge study at Wageningen Bioveterinary Research in Lelystad, NL.
Malcisbo was selected as an emerging company to present at the European Animal Health Investment Forum in London, February 2017.
Malcisbo participated in a CTI-funded research project on developing a vaccine against Actinobacillus pleuropneumoniae (APP).
Publication in PLOS Pathogens on parasite glycobiology.